"uuid:ID","instanceType","rationale","id","versionIdentifier"
"56029809-dd79-41cb-8db0-444871526ae6","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2"
